Form 6-K BioLineRx Ltd. For: Oct 23

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2026

 

Commission file number: 001-35223

 

BioLineRx Ltd.

(Translation of registrant’s name into English)

 

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

On October 23, 2026, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BioLineRx Ltd.
	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

 

Dated: October 23, 2026

 

 

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE, DATED OCTOBER 23, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BioLineRx and Hemispherian present GLIX1 and PARP inhibitor data at ESMO
• NTT DATA Expands AI Factory Footprint Globally to Help Clients Scale AI from Pilots to Production
• BCUC Accepts BC Hydro’s 2025 Integrated Resource Plan